MX2017003269A - Detección de las proteínas mal plegadas. - Google Patents
Detección de las proteínas mal plegadas.Info
- Publication number
- MX2017003269A MX2017003269A MX2017003269A MX2017003269A MX2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- misfolded
- soluble
- monomeric
- sample
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 11
- 108090000623 proteins and genes Proteins 0.000 title abstract 11
- 238000001514 detection method Methods 0.000 title 1
- 238000011534 incubation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 102000029797 Prion Human genes 0.000 abstract 2
- 108091000054 Prion Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049306P | 2014-09-11 | 2014-09-11 | |
| PCT/US2015/049844 WO2016040907A1 (en) | 2014-09-11 | 2015-09-11 | Detection of misfolded proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003269A true MX2017003269A (es) | 2017-12-04 |
Family
ID=55454515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003269A MX2017003269A (es) | 2014-09-11 | 2015-09-11 | Detección de las proteínas mal plegadas. |
Country Status (15)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| GB201611840D0 (en) * | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| EP3635393A4 (en) * | 2017-05-16 | 2021-03-10 | Claudio Soto-Jara | ABNORMALLY FOLDING TAU PROTEIN DETECTION |
| CA3074914A1 (en) | 2017-10-02 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| CN111630382A (zh) * | 2017-12-21 | 2020-09-04 | H.隆德贝克有限公司 | α-共核蛋白病的测定、方法和治疗 |
| CN108088816A (zh) * | 2018-01-23 | 2018-05-29 | 深圳市国赛生物技术有限公司 | 小型特定蛋白分析仪 |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| US20190353669A1 (en) * | 2018-05-16 | 2019-11-21 | Amprion, Inc. | Detection of Brain Injury or Neurological Disease using Tau Protein |
| JP7125544B2 (ja) | 2018-09-21 | 2022-08-24 | ディープマインド テクノロジーズ リミテッド | 品質スコアの勾配を使用した反復的なタンパク質構造予測 |
| JP7376040B2 (ja) * | 2019-09-03 | 2023-11-08 | 国立大学法人京都工芸繊維大学 | 神経変性疾患におけるバイオマーカー分子の検出方法 |
| AU2020343310A1 (en) * | 2019-09-04 | 2022-03-24 | Amprion, Inc. | Alpha-synuclein detection using beads |
| KR102277871B1 (ko) * | 2019-12-17 | 2021-07-15 | 원광대학교산학협력단 | 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트 |
| WO2021198098A1 (en) | 2020-04-03 | 2021-10-07 | Universität Zürich | Improved method of detecting biomarkers in a biological sample |
| MX2022014319A (es) * | 2020-05-18 | 2023-02-27 | Amprion Inc | Sustratos de alfa-sinucleína y métodos para la fabricación y el uso de los mismos. |
| JP2023549957A (ja) * | 2020-11-21 | 2023-11-29 | シュウェン バイオテック カンパニー リミテッド | 生体試料における異常折り畳みタンパク質を検出するための装置及び方法 |
| US20240192230A1 (en) * | 2021-04-15 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Digital Protein Misfolding Assays |
| CN114199875B (zh) * | 2022-02-18 | 2022-05-20 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05675B1 (et) | 2000-07-07 | 2013-08-15 | Applied Research Systems Ars Holding N.V. | Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade |
| CA2433754A1 (en) | 2001-01-03 | 2002-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| EP1820806A1 (en) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinity regions |
| WO2006088823A2 (en) * | 2005-02-15 | 2006-08-24 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| EP2392583A1 (en) * | 2006-05-19 | 2011-12-07 | Alnylam Europe AG. | RNAi modulation of Aha and therapeutic uses thereof |
| CA2662863A1 (en) * | 2006-09-06 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of protein folding disorders |
| JP2010043865A (ja) * | 2006-12-12 | 2010-02-25 | Olympus Corp | 異常型プリオンの検出方法 |
| WO2011064225A1 (en) * | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
| US9133343B2 (en) * | 2009-11-30 | 2015-09-15 | Enzo Biochem, Inc. | Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications |
| WO2012099884A1 (en) * | 2011-01-18 | 2012-07-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for amplification and detection of prions |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2016040903A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
-
2015
- 2015-09-11 AU AU2015314783A patent/AU2015314783B2/en active Active
- 2015-09-11 WO PCT/US2015/049844 patent/WO2016040907A1/en not_active Ceased
- 2015-09-11 CN CN201580058606.3A patent/CN107208125A/zh active Pending
- 2015-09-11 SG SG11201701953RA patent/SG11201701953RA/en unknown
- 2015-09-11 EP EP23189057.5A patent/EP4292654A3/en active Pending
- 2015-09-11 ES ES15839278T patent/ES2953855T3/es active Active
- 2015-09-11 KR KR1020177009707A patent/KR102448128B1/ko active Active
- 2015-09-11 CA CA2960830A patent/CA2960830C/en active Active
- 2015-09-11 US US14/852,478 patent/US20160077112A1/en not_active Abandoned
- 2015-09-11 HR HRP20231232TT patent/HRP20231232T1/hr unknown
- 2015-09-11 SG SG10202008464UA patent/SG10202008464UA/en unknown
- 2015-09-11 EP EP15839278.7A patent/EP3191599B1/en active Active
- 2015-09-11 BR BR112017004899A patent/BR112017004899A2/pt active Search and Examination
- 2015-09-11 MX MX2017003269A patent/MX2017003269A/es unknown
- 2015-09-11 PL PL15839278.7T patent/PL3191599T3/pl unknown
- 2015-09-11 JP JP2017533721A patent/JP6980953B2/ja active Active
-
2017
- 2017-03-09 IL IL251052A patent/IL251052B/en unknown
-
2021
- 2021-05-12 JP JP2021081274A patent/JP7104943B2/ja active Active
-
2022
- 2022-03-30 IL IL291809A patent/IL291809B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3191599T3 (pl) | 2023-12-27 |
| EP3191599B1 (en) | 2023-08-02 |
| KR102448128B1 (ko) | 2022-09-27 |
| KR20170103741A (ko) | 2017-09-13 |
| US20160077112A1 (en) | 2016-03-17 |
| CA2960830A1 (en) | 2016-03-17 |
| IL251052A0 (en) | 2017-04-30 |
| HRP20231232T1 (hr) | 2024-01-19 |
| EP4292654A3 (en) | 2024-01-03 |
| CA2960830C (en) | 2023-09-05 |
| EP3191599C0 (en) | 2023-08-02 |
| IL251052B (en) | 2022-05-01 |
| JP2017530373A (ja) | 2017-10-12 |
| IL291809A (en) | 2022-06-01 |
| CN107208125A (zh) | 2017-09-26 |
| EP4292654A2 (en) | 2023-12-20 |
| AU2015314783A1 (en) | 2017-04-27 |
| WO2016040907A1 (en) | 2016-03-17 |
| SG10202008464UA (en) | 2020-10-29 |
| JP7104943B2 (ja) | 2022-07-22 |
| JP6980953B2 (ja) | 2021-12-15 |
| EP3191599A1 (en) | 2017-07-19 |
| SG11201701953RA (en) | 2017-04-27 |
| IL291809B2 (en) | 2023-06-01 |
| EP3191599A4 (en) | 2018-03-14 |
| ES2953855T3 (es) | 2023-11-16 |
| JP2022000629A (ja) | 2022-01-04 |
| BR112017004899A2 (pt) | 2017-12-12 |
| AU2015314783B2 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003269A (es) | Detección de las proteínas mal plegadas. | |
| MX2021006791A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
| WO2015114506A3 (en) | Biosensors for the detection of infection and associated maladies | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| MX2019007653A (es) | Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana. | |
| EP4438743A3 (en) | Pancreatic cancer detection kit or device, and detection method | |
| BR112016028944A2 (pt) | kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção | |
| MX2021007667A (es) | Composiciones y metodos para detectar un contaminante biologico. | |
| PH12019550236A1 (en) | Detection of misfolded tau protein | |
| PH12015502849B1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
| EP4570924A3 (en) | Chromophore-based characterization and detection methods | |
| EP4067507A3 (en) | Pna probes, kits and methods for detecting genotypes of human papillomavirus | |
| MY179845A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| MX395376B (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| EA201700208A1 (ru) | Способ и устройство для обнаружения малярии | |
| MX2021009528A (es) | Prueba de diagnostico basada en fragmento de rgma. | |
| EP4407047A3 (en) | Molecular detection of enterovirus and parechovirus | |
| MX2018006146A (es) | Modificación de diana para seguimiento y detección. | |
| SG10201901836PA (en) | Test strip assembly | |
| WO2014145243A3 (en) | High resolution melting analysis assay for the detection of viral dna | |
| MX2017008748A (es) | Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana. | |
| WO2015193552A3 (en) | Means and methods for determining risk of type-1 diabetes by serum protein biomarkers | |
| WO2019013613A3 (es) | Métodos y kits para determinar el riesgo de cáncer |